Skip to main content

AbbVie Inc.

corporate_fare Company Profile

AbbVie Inc.

ABBV·NYSE·Life Sciences·CIK 0001551152

AbbVie is a global, diversified research-based biopharmaceutical company that develops and markets advanced therapies. The company was incorporated in Delaware on April 10, 2012, and became an independent, publicly-traded company on January 1, 2013, following a distribution from Abbott Laboratories. AbbVie operates as a single global business segment, focusing on the research and development, manufacturing, commercialization, and sale of innovative medicines and therapies. This structure allows the Chief Executive Officer to allocate resources and assess performance globally. A global research and development and supply chain organization handles product discovery, development, manufacturing, and supply, while commercial efforts for marketing, sales, and distribution are organized by geographic region or therapeutic area. These activities are supported by a global corporate administrative staff. AbbVie's product portfolio holds leadership positions across immunology, neuroscience, oncology, and aesthetics. Its products include a broad line of therapies for complex and serious diseases, with an extensive immunology portfolio covering rheumatology, dermatology, and gastroenterology.

AbbVie Inc. (NYSE:ABBV) is a publicly traded company in the Life Sciences sector. Wiseek monitors ABBV SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • AbbVie Reports Strong Q1 Revenue Growth & Operating Cash Flow Amid Strategic Investments and Pipeline Progress
  • AbbVie Reports Strong Q1 Earnings, Raises Full-Year EPS Guidance, and Advances Key Pipeline Assets
  • AbbVie Sets Full-Year Adjusted EPS Guidance at $14.08-$14.28
  • AbbVie Submits Rinvoq Application to FDA for Severe Alopecia Areata
  • AbbVie's Rinvoq Demonstrates Superiority Over Humira in Rheumatoid Arthritis Study

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$61.16B
Net Income
$4.23B
Diluted EPS
$2.36
Op. Cash Flow
$19.03B
Free Cash Flow
$17.82B
Gross Profit
$42.96B
Operating Income
$15.07B
Cash & Equivalents
$5.23B
Total Debt
$2.5B
Debt / Equity
-0.76×
Net Margin
6.9%
Shares Outstanding
1.77B sh
Source: 10-K · filed 2026-02-20 · accession 0001551152-26-000008
$255.46 -1.46% today
52-week range · as of 2026-07-06 $184.63 – $261.63
Market cap
$453.92B
Volume
4.4M (0.6× avg)
3-mo avg 8M
Live data · 2026-07-23 21:06 UTC · After hours

show_chartPrice Chart

Loading chart...

feed ABBV - Filings & News (Page 2)

ABBV
May 08, 2026, 12:28 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $201.00
Real-time Price: $255.46 info
Change: +$54.46 (+27%) info
Market Cap: $453.924B info
ABBV
Apr 29, 2026, 7:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $197.04
Real-time Price: $255.46 info
Change: +$58.42 (+30%) info
Market Cap: $453.924B info
ABBV
Apr 29, 2026, 7:47 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $197.96
Real-time Price: $255.46 info
Change: +$57.50 (+29%) info
Market Cap: $453.924B info
ABBV
Apr 28, 2026, 9:36 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $198.01
Real-time Price: $255.46 info
Change: +$57.45 (+29%) info
Market Cap: $453.924B info
ABBV
Apr 28, 2026, 7:16 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $199.06
Real-time Price: $255.46 info
Change: +$56.40 (+28%) info
Market Cap: $453.924B info
ABBV
Apr 23, 2026, 4:11 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $200.95
Real-time Price: $255.46 info
Change: +$54.51 (+27%) info
Market Cap: $453.924B info
ABBV
Apr 12, 2026, 11:00 AM EDT
Source: dpa-AFX
Importance Score:
7
Price at Filing: $208.33
Real-time Price: $255.46 info
Change: +$47.14 (+23%) info
Market Cap: $453.924B info
ABBV
Apr 08, 2026, 12:17 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $210.95
Real-time Price: $255.46 info
Change: +$44.51 (+21%) info
Market Cap: $453.924B info
ABBV
Apr 03, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $208.27
Real-time Price: $255.46 info
Change: +$47.19 (+23%) info
Market Cap: $453.924B info
ABBV
Mar 23, 2026, 4:59 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $204.50
Real-time Price: $255.46 info
Change: +$50.96 (+25%) info
Market Cap: $453.924B info
ABBV
Mar 09, 2026, 4:31 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $227.75
Real-time Price: $255.46 info
Change: +$27.71 (+12%) info
Market Cap: $453.924B info
ABBV
Mar 09, 2026, 8:23 AM EDT
Source: MFN by Modular Finance
Importance Score:
7
Price at Filing: $228.11
Real-time Price: $255.46 info
Change: +$27.35 (+12%) info
Market Cap: $453.924B info
ABBV
Mar 04, 2026, 4:59 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $235.96
Real-time Price: $255.46 info
Change: +$19.50 (+8%) info
Market Cap: $453.924B info
ABBV
Mar 02, 2026, 8:32 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $230.78
Real-time Price: $255.46 info
Change: +$24.68 (+11%) info
Market Cap: $453.924B info
ABBV
Feb 26, 2026, 5:07 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $224.67
Real-time Price: $255.46 info
Change: +$30.79 (+14%) info
Market Cap: $453.924B info
ABBV
Feb 24, 2026, 7:47 PM EST
Filing Type: FWP
Importance Score:
8
Price at Filing: $228.64
Real-time Price: $255.46 info
Change: +$26.82 (+12%) info
Market Cap: $453.924B info
ABBV
Feb 20, 2026, 2:38 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $226.46
Real-time Price: $255.46 info
Change: +$29.00 (+13%) info
Market Cap: $453.924B info
ABBV
Feb 04, 2026, 7:54 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $229.00
Real-time Price: $255.46 info
Change: +$26.46 (+12%) info
Market Cap: $453.924B info
ABBV
Jan 07, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $229.50
Real-time Price: $255.46 info
Change: +$25.96 (+11%) info
Market Cap: $453.924B info